VYNE Therapeutics Reports Positive Top-line Phase 1a MAD Data for VYN202, its Novel BD2-Selective BET Inhibitor
23 déc. 2024 07h30 HE
|
VYNE Therapeutics Inc.
Promising results support VYN202’s potential as a novel, once-daily oral treatment for a broad range of immune-mediated disordersConsistent with Phase 1a SAD results, VYN202 demonstrated a favorable...
VYNE Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update
07 nov. 2024 08h00 HE
|
VYNE Therapeutics Inc.
VYN201 Phase 2b vitiligo trial exceeds enrollment target; Expected to be fully enrolled in December 2024 with top-line results on track for mid-2025Reported positive first-in-human Phase 1a SAD data...
VYNE Therapeutics Announces Positive Phase 1a SAD Data for VYN202, a Novel BD2-Selective BET Inhibitor
12 sept. 2024 08h00 HE
|
VYNE Therapeutics Inc.
VYN202 was generally well tolerated with no drug-related adverse eventsPharmacokinetic results demonstrated dose-dependent exposure of VYN202 in blood Pharmacodynamic activity observed on target...
VYNE Therapeutics to Participate in September Investor Conferences
03 sept. 2024 08h00 HE
|
VYNE Therapeutics Inc.
BRIDGEWATER, N.J., Sept. 03, 2024 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a clinical-stage biopharmaceutical company focused on developing differentiated...
VYNE Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update
14 août 2024 08h00 HE
|
VYNE Therapeutics Inc.
Initiated Phase 2b trial of VYN201 in nonsegmental vitiligo, with top-line results expected in mid-2025Phase 1a SAD/MAD trial of VYN202 progressing, with data from the SAD and MAD portions expected in...
VYNE Therapeutics Announces Granting of Composition of Matter Patent for VYN202, a Novel BD2-Selective BET Inhibitor
16 juil. 2024 08h00 HE
|
VYNE Therapeutics Inc.
BRIDGEWATER, N.J., July 16, 2024 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a clinical-stage biopharmaceutical company developing proprietary, innovative...
VYNE Therapeutics Announces Appointment of Subhashis Banerjee, M.D. as Senior Vice President of Clinical Development
09 juil. 2024 08h00 HE
|
VYNE Therapeutics Inc.
BRIDGEWATER, N.J., July 09, 2024 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a clinical-stage biopharmaceutical company developing proprietary, innovative...
VYNE Therapeutics to Participate in Leerink Partners Therapeutics Forum
26 juin 2024 08h00 HE
|
VYNE Therapeutics Inc.
BRIDGEWATER, N.J., June 26, 2024 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a clinical-stage biopharmaceutical company developing proprietary, innovative,...
VYNE Therapeutics Announces Dosing of First Participants in Phase 1a Trial of Novel BD2-Selective BET Inhibitor VYN202
13 juin 2024 09h02 HE
|
VYNE Therapeutics Inc.
VYN202 has been designed to achieve class-leading potency and BD2-selectivity Trial will evaluate safety, tolerability, pharmacokinetics and pharmacodynamics of VYN202 in healthy volunteers;...
VYNE Therapeutics Announces Dosing of First Subject in Phase 2b Vitiligo Trial of Novel BET Inhibitor VYN201
05 juin 2024 08h00 HE
|
VYNE Therapeutics Inc.
Trial will evaluate once-daily VYN201 gel in subjects with either active or stable nonsegmental vitiligo Top-line data from the 24-week double-blind portion of the trial expected in mid-2025 ...